Gilead Sciences, Inc.

GILD · Nasdaq · ·

下次财报：2026年10月29日

US$151.30-0.6%9月29日收盘

1M: +1.5%
6M: +9.2%
1Y: +39.5%
5Y: +156.8%

对比

Gilead sells medicines for human immunodeficiency virus, liver disease, cancer, and coronavirus disease 2019.

Gilead Sciences, Inc.（GILD）股票——这是一门好生意吗？ — InspectStocks

Gilead Sciences, Inc.

GILD · Nasdaq · ·

下次财报：2026年10月29日

US$151.30-0.6%9月29日收盘

1M: +1.5%
6M: +9.2%
1Y: +39.5%
5Y: +156.8%

对比

Gilead sells medicines for human immunodeficiency virus, liver disease, cancer, and coronavirus disease 2019.

怎么赚钱

HIV medicines73%
Liver disease medicines11%
Cancer medicines11%
Veklury1%
Royalties, contracts, and other revenue1%

各项收入占比是对six months ended June 30, 2026的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

Biktarvy
A daily tablet used to treat HIV infection in certain patients.
Yeztugo
A tablet and long-acting injection used before exposure to help prevent HIV infection in at-risk adults and adolescents.
Descovy
A tablet used with other medicines to treat HIV, and also used before exposure to help prevent HIV infection in certain at-risk people.

再显示 3 项

Trodelvy
An intravenous medicine for certain adults with advanced breast cancer. The latest quarterly report describes its use as a first-line treatment for metastatic triple-negative breast cancer, as well as treatment for some patients with hormone-receptor-positive breast cancer.
Yescarta
A treatment made from a patient's immune cells that are changed to recognize and attack certain blood cancers.
Livdelzi
An oral medicine for primary biliary cholangitis, a chronic disease that damages small bile ducts in the liver.

谁在买4

In the United States, large drug wholesalers buy most products for distribution to pharmacies and healthcare providers; Gilead names Cardinal Health, Cencora, and McKesson as major wholesalers.
Outside the United States, products are sold through Gilead's commercial teams, third-party distributors, and corporate partners.
Hospitals, clinics, and other healthcare providers prescribe or administer Gilead medicines to patients.
Government health programs and private insurers pay for or reimburse many prescriptions and related treatments.

靠什么支撑，什么会击垮它

业务依赖什么

1Gilead relies on wholesalers to distribute most of its products in the United States and on distributors or corporate partners in some other markets.
2It relies on outside manufacturers and testing laboratories for much of the production and testing of its medicines, though it uses multiple suppliers for many products.
3Its business depends on regulatory approval and continuing compliance with rules governing drug testing, manufacture, safety, promotion, and sale.

完整财务报表 →

与同行业相比处在什么位置

三项评分，每一项都是相对我们在Drug Manufacturers General覆盖的 21 家公司的百分位。刻意分开而不揉成一个总分：便宜、上涨和经营得好是三件不同的事，一个数字会把它们是哪一件藏起来。

动量

58在同行业中满分 100

处于同行业中游

截至一个月前的 12 个月32.3%

截至一个月前的 6 个月-1.0%

最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。

估值

33在同行业中满分 100

低于行业内多数公司

每单位价格对应的利润-1.73%

每单位价格对应的现金6.90%

每单位价格对应的营收16.23%

每单位价格对应的资产12.10%

整个企业对应的经营利润6.22%

这些是收益率，所以数值越高越便宜——亏损的公司会排在最后，而不是被剔除。便宜不等于好：高收益率往往意味着股价是有原因才跌下来的。五项指标齐全。

资本配置

5/5克制

1 项检验未披露

资本回报率16.4%

股东回报率3.16%

股本数量，3 年-1.7%

净债务 / EBITDA1.40x

内部人，12 个月-US$61M

管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。

六项资本配置检验

投入资金的回报投入资本回报 16.4%
债务与盈利之比净债务为经营利润的 1.40 倍
回馈给股东的现金每年 3.2% 用于回购和分红
三年间的股本数量三年间股本数量减少 1.7%
现金流对派付的覆盖自由现金流覆盖了派付的部分
内部人在公开市场的买入净卖出 US$61M——不计入扣分

这是对该公司在同行中所处位置的描述，不是投资建议。评分更新于 2026年9月30日。

关于Gilead Sciences, Inc.

Gilead discovers, develops, and sells prescription medicines. Its medicines prevent or treat human immunodeficiency virus (HIV), viral hepatitis, cancer, coronavirus disease 2019 (COVID-19), and other serious illnesses. It sells medicines directly through its commercial teams and through wholesalers, distributors, and business partners.

总部: Foster City, California
成立于: 1987
员工人数: Approximately 17,000 (December 31, 2025, high)
上市于: Nasdaq
财年结束: December 31

基于 Gilead Sciences, Inc. 自己向 SEC 提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

怎么赚钱

HIV medicines73%
Liver disease medicines11%
Cancer medicines11%
Veklury1%
Royalties, contracts, and other revenue1%

各项收入占比是对six months ended June 30, 2026的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

Biktarvy
A daily tablet used to treat HIV infection in certain patients.
Yeztugo
A tablet and long-acting injection used before exposure to help prevent HIV infection in at-risk adults and adolescents.
Descovy
A tablet used with other medicines to treat HIV, and also used before exposure to help prevent HIV infection in certain at-risk people.

再显示 3 项

Trodelvy
An intravenous medicine for certain adults with advanced breast cancer. The latest quarterly report describes its use as a first-line treatment for metastatic triple-negative breast cancer, as well as treatment for some patients with hormone-receptor-positive breast cancer.
Yescarta
A treatment made from a patient's immune cells that are changed to recognize and attack certain blood cancers.
Livdelzi
An oral medicine for primary biliary cholangitis, a chronic disease that damages small bile ducts in the liver.

谁在买4

In the United States, large drug wholesalers buy most products for distribution to pharmacies and healthcare providers; Gilead names Cardinal Health, Cencora, and McKesson as major wholesalers.
Outside the United States, products are sold through Gilead's commercial teams, third-party distributors, and corporate partners.
Hospitals, clinics, and other healthcare providers prescribe or administer Gilead medicines to patients.
Government health programs and private insurers pay for or reimburse many prescriptions and related treatments.

靠什么支撑，什么会击垮它

业务依赖什么

1Gilead relies on wholesalers to distribute most of its products in the United States and on distributors or corporate partners in some other markets.
2It relies on outside manufacturers and testing laboratories for much of the production and testing of its medicines, though it uses multiple suppliers for many products.
3Its business depends on regulatory approval and continuing compliance with rules governing drug testing, manufacture, safety, promotion, and sale.

完整财务报表 →

与同行业相比处在什么位置

动量

58在同行业中满分 100

处于同行业中游

截至一个月前的 12 个月32.3%

截至一个月前的 6 个月-1.0%

最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。

估值

33在同行业中满分 100

低于行业内多数公司

每单位价格对应的利润-1.73%

每单位价格对应的现金6.90%

每单位价格对应的营收16.23%

每单位价格对应的资产12.10%

整个企业对应的经营利润6.22%

资本配置

5/5克制

1 项检验未披露

资本回报率16.4%

股东回报率3.16%

股本数量，3 年-1.7%

净债务 / EBITDA1.40x

内部人，12 个月-US$61M

管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。

六项资本配置检验

投入资金的回报投入资本回报 16.4%
债务与盈利之比净债务为经营利润的 1.40 倍
回馈给股东的现金每年 3.2% 用于回购和分红
三年间的股本数量三年间股本数量减少 1.7%
现金流对派付的覆盖自由现金流覆盖了派付的部分
内部人在公开市场的买入净卖出 US$61M——不计入扣分

这是对该公司在同行中所处位置的描述，不是投资建议。评分更新于 2026年9月30日。

关于Gilead Sciences, Inc.

总部: Foster City, California
成立于: 1987
员工人数: Approximately 17,000 (December 31, 2025, high)
上市于: Nasdaq
财年结束: December 31

Gilead Sciences, Inc.

Gilead Sciences, Inc.

怎么赚钱

竞争对手

卖什么6

谁在买4

靠什么支撑，什么会击垮它

业务依赖什么

与同行业相比处在什么位置

关于Gilead Sciences, Inc.

怎么赚钱

竞争对手

卖什么6

谁在买4

靠什么支撑，什么会击垮它

业务依赖什么

与同行业相比处在什么位置

关于Gilead Sciences, Inc.

可能出什么问题

成长与现金——5 项中通过 5 项